EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine

Nancy H L Leung, Samuel M S Cheng, Mario Martín-Sánchez, Niki Y M Au, Yvonne Y Ng, Leo L H Luk, Karl C K Chan, John K C Li, Yonna W Y Leung, Leo C H Tsang, Sara Chaothai, Kelvin K H Kwan und 5 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac458 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Nancy H L Leung und 16 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing (LKS) Faculty of…. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China, RGC Senior Research Fellow Scheme grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data exist on antibody responses to mixed vaccination strategies that involve inactivated coronavirus disease 2019 (COVID-19) vaccines, particularly in the context of emerging variants.

Methods

We conducted an open-label trial of a third vaccine dose of a messenger RNA (mRNA) vaccine (BNT162b2, Fosun Pharma/BioNTech) in adults aged ≥30 years who had previously received 2 doses of inactivated COVID-19 vaccine. We collected blood samples before administering the third dose and 28 days later and tested for antibodies to the ancestral virus using a binding assay (enzyme-linked immunosorbent assay [ELISA]), a surrogate virus neutralization test (sVNT), and a live virus plaque reduction neutralization test (PRNT). We also tested for antibodies against the Omicron variant using live-virus PRNT.

Results

In 315 participants, a third dose of BNT162b2 substantially increased antibody titers on each assay. Mean ELISA levels increased from an optical density of 0.3 to 2.2 (P < .001), and mean sVNT levels increased from an inhibition of 17% to 96% (P < .001). In a random subset of 20 participants, the geometric mean PRNT50 titers rose substantially, by 45-fold from day 0 to day 28 against the ancestral virus (P < .001) and by 11-fold against the Omicron variant (P < .001). In daily monitoring, post-vaccination reactions subsided within 7 days for more than 99% of participants.

Conclusions

A third dose of COVID-19 vaccine with an mRNA vaccine substantially improved antibody levels against the ancestral virus and the Omicron variant with a well-tolerated safety profile in adults who had received 2 doses of inactivated vaccine 6 months earlier. Clinical Trials Registration NCT05057182.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-19AdultHumansAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunogenicity, VaccineRNA, MessengerSARS-CoV-2Vaccines, Inactivated

Stichwörter der Autor:innen

BNT162b2COVID vaccineCoronaVacboosterimmunogenicity

Substanzen

Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesRNA, MessengerVaccines, Inactivated

Autor:innen und Institutionen

  • World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing (LKS) Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong Special Admini…
  • Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China.
  • Hong Kong University (HKU)-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China.
  • Centre for Immunology and Infection, Hong Kong Science and Technology Park, New Territories, Hong Kong Special Administrative Region, China.

ORCID-Profile: Benjamin J Cowling

Förderung

  • Research Grants Council (RGC) of the Hong Kong Special Administrative Region, China
  • RGC Senior Research Fellow Scheme grant

Zitieren

APA

Leung, N. H. L., Cheng, S. M. S., Martín-Sánchez, M., Au, N. Y. M., Ng, Y. Y., Luk, L. L. H., Chan, K. C. K., Li, J. K. C., Leung, Y. W. Y., Tsang, L. C. H., Chaothai, S., Kwan, K. K. H., Ip, D. K. M., Poon, L. L. M., Leung, G. M., Peiris, J. S. M., & Cowling, B. J. (2023). Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac458

Vancouver

Leung NHL, Cheng SMS, Martín-Sánchez M, Au NYM, Ng YY, Luk LLH, et al. Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac458

BibTeX
@article{Leung2023,
  author = {Leung, Nancy H L and Cheng, Samuel M S and Martín-Sánchez, Mario and Au, Niki Y M and Ng, Yvonne Y and Luk, Leo L H and Chan, Karl C K and Li, John K C and Leung, Yonna W Y and Tsang, Leo C H and Chaothai, Sara and Kwan, Kelvin K H and Ip, Dennis K M and Poon, Leo L M and Leung, Gabriel M and Peiris, J S Malik and Cowling, Benjamin J},
  title = {Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac458}
}
Kostenlos starten →